Anti-OX40 enhances immunity in some head and neck cancer patients
March 07, 2018
Anti-OX40, a novel immunotherapy engineered by researchers at Providence Cancer Institute, continues to show promise as a potentially powerful way to treat cancer.
Providence recently completed enrollment in the world’s first study of anti-OX40 in patients with newly diagnosed head and neck cancers. Patients received the drug prior to definitive surgery. Early results have found that the drug enhanced immunity in about a quarter of the patients who were treated, and was well tolerated by the study group. A total of 19 patients participated in the phase 1b neoadjuvant study.
New OX40 study to open soon
Based on these promising results, a similar, expanded phase 1 trial will be opening soon for head and neck patients, as well as melanoma patients. For updates, visit our Clinical Trials website and search by keyword “OX40.”
OX40 is a protein with cancer-fighting properties found on the surface of certain T cells. The antibody to the protein – anti-OX40 – activates T-cells to attack cancer cells. Providence Cancer Institute was the first site in the world to offer human clinical trials of the treatment.
Read more about anti-OX40.